🇺🇸 FDA
Patent

US 12317874

Method of using a genetically modified mouse that expresses human albumin

granted A61KA61K49/0008

Quick answer

US patent 12317874 (Method of using a genetically modified mouse that expresses human albumin) held by REGENERON PHARMACEUTICALS, INC. expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K49/0008